| 1 |
NCT03766269 |
Recruiting
New |
Dronabinol Opioid Sparing Evaluation (DOSE) Trial |
|
|
Interventional
|
Phase 2 |
- Daisy Pharma Opioid Venture, LLC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Intensity Scale (0-10)
- Self-Reported Opioid Use (Opioid Dose)
- Self-Reported Opioid Use Frequency (Opioid Dose Frequency)
- (and 16 more...)
|
280 |
All |
18 Years and older (Adult, Older Adult) |
NCT03766269 |
140635 |
|
December 1, 2018 |
June 1, 2019 |
July 1, 2019 |
December 6, 2018 |
December 6, 2018 |
|
- Daisy Research, Inc.
Scottsdale, Arizona, United States
|
|
| 2 |
NCT03661892 |
Not yet recruiting |
Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets |
- Bone Metastases
- Breast Cancer
- Pain
|
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Need for opiate pain medication
- Change in pain
- Change in quality of life
- Change in bone modulation
|
20 |
All |
21 Years and older (Adult, Older Adult) |
NCT03661892 |
29387
NCI-2018-01916 |
|
November 30, 2018 |
September 30, 2019 |
September 30, 2019 |
September 7, 2018 |
November 7, 2018 |
|
- University of Arizona
Tucson, Arizona, United States
|
|
| 3 |
NCT03530800 |
Recruiting |
Dronabinol in Trichotillomania |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS)
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03530800 |
18-0542 |
|
October 1, 2018 |
June 1, 2020 |
August 1, 2020 |
May 21, 2018 |
December 7, 2018 |
|
- University of Chicago
Chicago, Illinois, United States
|
|
| 4 |
NCT03560934 |
Not yet recruiting |
Tetrahydrocannabinol (THC) and Sleep |
- Sleep
- THC
- Marijuana
- Cannabis
|
|
Interventional
|
Early Phase 1 |
- Oregon Health and Science University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Sleep Stages
- Psychomotor Vigilance
- Blood Pressure
- (and 9 more...)
|
14 |
All |
21 Years to 34 Years (Adult) |
NCT03560934 |
IRB00018052 |
|
September 1, 2018 |
February 1, 2020 |
February 1, 2022 |
June 18, 2018 |
June 18, 2018 |
|
|
|
| 5 |
NCT03066193 |
Recruiting |
Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome |
|
- Drug: Dronabinol
- Dietary Supplement: Palmotoyletahnolamide
|
Interventional
|
Phase 3 |
- Yale University
- Therapix Biosciences Ltd.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in Tic Severity
|
18 |
All |
18 Years to 60 Years (Adult) |
NCT03066193 |
1610018525 |
|
February 1, 2017 |
January 2018 |
January 2019 |
February 28, 2017 |
March 3, 2017 |
|
- Yale Child Study Center
New Haven, Connecticut, United States
|
|
| 6 |
NCT02569073 |
Suspended |
Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Chest Pain
- Chest Pain Intensity
- GERD Symptom Checklist
- (and 17 more...)
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02569073 |
22894 |
ICAMP |
June 21, 2017 |
October 2019 |
October 2020 |
October 6, 2015 |
September 14, 2018 |
|
- Temple University Hospital
Philadelphia, Pennsylvania, United States
|
|
| 7 |
NCT02792257 |
Recruiting |
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD) |
|
- Drug: Dronabinol (Marinol®)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Johns Hopkins University
- Mclean Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Symptoms of agitation as measured by the Pittsburgh Agitation Scale
- Symptoms of agitation as measured by the Neuropsychiatric Inventory, Clinician Version
- Adverse events in Dronabinol treatment as compared to placebo
|
160 |
All |
60 Years to 90 Years (Adult, Older Adult) |
NCT02792257 |
IRB00052955 |
THC-AD |
March 1, 2017 |
August 2020 |
December 2020 |
June 7, 2016 |
June 26, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - McLean Hospital
Belmont, Massachusetts, United States
|
|
| 8 |
NCT03215940 |
Recruiting |
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) |
|
- Drug: Delta-9-Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebos
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Brain Changes
- Improvement in pain relief
|
75 |
All |
18 Years to 50 Years (Adult) |
NCT03215940 |
IRB_00103451 |
|
February 1, 2018 |
December 2018 |
February 2019 |
July 12, 2017 |
August 27, 2018 |
|
- University Of Utah
Salt Lake City, Utah, United States
|
|
| 9 |
NCT02608931 |
Recruiting |
The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia |
- Nausea
- Vomiting
- Familial Dysautonomia
|
- Drug: Dronabinol
- Other: Placebo
|
Interventional
|
Phase 2 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of adverse effects
- Change in nausea scores
- Change in weight.
- Change in anxiety scores
|
25 |
All |
18 Years to 60 Years (Adult) |
NCT02608931 |
14-01577 |
|
November 2015 |
March 2020 |
March 2020 |
November 20, 2015 |
May 10, 2018 |
|
- NYU Medical Center
New York, New York, United States
|
|
| 10 |
NCT02460692 |
Recruiting |
Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain |
- Cannabis
- Low Back Pain
- Neuropathic Pain
|
- Drug: Placebos
- Drug: dronabinol
- Drug: Vaporized Cannabis 3.7% THC/5.6% CBD
|
Interventional
|
Phase 2 |
- University of California, San Diego
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numerical Pain Intensity
- Repeated Measures Recommended Minimal Dataset (NIH Task Force on chronic low back pain)
- Neuropathic Pain Scale
- (and 10 more...)
|
120 |
All |
19 Years to 70 Years (Adult, Older Adult) |
NCT02460692 |
1R01DA038634-01A1
R01DA038634 |
|
September 2016 |
May 2020 |
May 2020 |
June 2, 2015 |
October 19, 2018 |
|
- UC Center for Medicinal Cannabis Research, UC San Diego
San Diego, California, United States
|
|
| 11 |
NCT03604341 |
Recruiting |
Cannabinoids for Pain Control During Medical Abortion |
|
- Drug: Dronabinol 5mg Cap
- Other: Placebo
|
Interventional
|
Phase 4 |
- Oregon Health and Science University
- Society of Family Planning
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Maximum self-reported pain score on a numeric rating scale
|
62 |
Female |
21 Years to 89 Years (Adult, Older Adult) |
NCT03604341 |
OHSU IRB 18195 |
|
November 1, 2018 |
March 2019 |
June 2019 |
July 27, 2018 |
December 6, 2018 |
|
- Oregon Health & Science University
Portland, Oregon, United States
|
|
| 12 |
NCT02604992 |
Completed |
Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers |
|
- Drug: Treatment A
- Drug: Treatment B
- Drug: Treatment C
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Area under the curve from time 0 to the last measured concentration
- Area under the curve extrapolated to infinity
- Maximum plasma concentration
- (and 6 more...)
|
54 |
All |
18 Years to 50 Years (Adult) |
NCT02604992 |
INS004-15-059 |
|
November 2015 |
December 2015 |
December 2015 |
November 16, 2015 |
January 20, 2016 |
|
- Worldwide Clinical Trials Early Phase Services, LLC
San Antonio, Texas, United States
|
|
| 13 |
NCT02811510 |
Recruiting |
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I |
|
- Drug: Placebo
- Drug: Dronabinol
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS)
- Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT)
|
40 |
All |
18 Years to 55 Years (Adult) |
NCT02811510 |
1505015940.A |
THC-Gender-I |
June 2016 |
June 2020 |
June 2020 |
June 23, 2016 |
June 26, 2018 |
|
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States
|
|
| 14 |
NCT02472847 |
Completed
Has Results |
Cannabinoid Control of Fear Extinction Neural Circuits in Humans |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 4 |
- University of Illinois at Chicago
- National Institute of Mental Health (NIMH)
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- BOLD Signal Measured by Functional Magnetic Resonance Imaging (fMRI)
|
85 |
All |
21 Years to 45 Years (Adult) |
NCT02472847 |
2012-0242
R21MH093917 |
|
May 2012 |
July 2014 |
July 2014 |
June 16, 2015 |
August 25, 2015 |
August 25, 2015 |
|
|
| 15 |
NCT01598896 |
Terminated
Has Results |
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia |
- Cannabis Dependence
- Marijuana Dependence
|
- Drug: Dronabinol
- Drug: Clonidine
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Mclean Hospital
- Brain & Behavior Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Cannabis Use at 10 Weeks
- Change in Craving Symptoms From Baseline at 10 Weeks
- Change From Baseline in Cannabis Use at 14 Weeks
- Change in Craving Symptoms From Baseline at 14 Weeks
|
12 |
All |
18 Years to 45 Years (Adult) |
NCT01598896 |
2010P-002262
Brain and Behavior Research |
DCCS |
May 2012 |
August 2017 |
August 2017 |
May 15, 2012 |
August 29, 2018 |
August 1, 2018 |
- McLean Hospital
Belmont, Massachusetts, United States
|
|
| 16 |
NCT01394185 |
Completed
Has Results |
Effects of Dronabinol (Oral THC) on Cannabis Use |
|
- Drug: Dronabinol 120mg/day
- Drug: Placebo
- Drug: Dronabinol 240mg/day
|
Interventional
|
Phase 1
Phase 2 |
- Johns Hopkins University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Marijuana Self-administration - Progressive Ratio
- Marijuana Self-administration - Drug Vs Money Choice
|
25 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT01394185 |
NA_00041251
R01DA025044 |
|
February 2011 |
September 2012 |
September 2012 |
July 14, 2011 |
August 3, 2017 |
August 3, 2017 |
- Johns Hopkins University (Bayview Campus)
Baltimore, Maryland, United States
|
|
| 17 |
NCT02094599 |
Completed |
A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users |
|
- Drug: Dronabinol 10 mg
- Drug: Dronabinol 30 mg
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
|
- Peak score (Emax) on Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking
- Peak score (Emax) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely
- Peak score (Emax) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score
- (and 9 more...)
|
43 |
All |
18 Years to 55 Years (Adult) |
NCT02094599 |
INS-13-017 |
|
February 2014 |
May 2014 |
May 2014 |
March 24, 2014 |
May 13, 2014 |
|
- INC Research Toronto, Inc.
Toronto, Ontario, Canada
|
|
| 18 |
NCT01380457 |
Completed |
Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions |
- To Determine Bioequivalence Under Fasting Conditions
|
- Drug: Dronabinol
- Drug: Marinol
|
Interventional
|
Phase 1 |
- Par Pharmaceutical, Inc.
- BASi Clinical Research Unit
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
|
69 |
All |
18 Years to 55 Years (Adult) |
NCT01380457 |
11885 |
|
January 2006 |
April 2006 |
April 2006 |
June 27, 2011 |
June 27, 2011 |
|
- BASi
Baltimore, Maryland, United States
|
|
| 19 |
NCT03098940 |
Not yet recruiting |
A Bioavailability Study on Dronabinol |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
All |
18 Years to 55 Years (Adult) |
NCT03098940 |
MedChew |
|
January 2018 |
April 2018 |
September 2018 |
April 4, 2017 |
April 4, 2017 |
|
|
|
| 20 |
NCT03008005 |
Recruiting |
Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study |
- PostTraumatic Stress Disorder
|
- Drug: Placebo Oral Capsule
- Drug: Dronabinol Cap 5 milligrams (MG)
- Drug: Dronabinol Cap 10 milligrams (MG)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain Measures
- Psychophysiology
- Expectancy Ratings
- (and 8 more...)
|
104 |
All |
18 Years to 50 Years (Adult) |
NCT03008005 |
1R61MH111935-01 |
|
June 1, 2017 |
December 31, 2019 |
December 31, 2019 |
January 2, 2017 |
November 6, 2017 |
|
- Eugene Applebaum College of Pharmacy and Health Sciences
Detroit, Michigan, United States
|
|
| 21 |
NCT01448772 |
Completed |
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions |
|
- Drug: Dronabinol Capsules, 5 mg
- Drug: Dronabinol Oral Solution
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Rate and extent of absorption
|
88 |
All |
18 Years to 55 Years (Adult) |
NCT01448772 |
INS-10-012 |
|
October 2011 |
December 2011 |
December 2011 |
October 7, 2011 |
March 26, 2012 |
|
- Worldwide Clinical Trials Drug Development Solutions
Austin, Texas, United States
|
|
| 22 |
NCT01093976 |
Completed
Has Results |
Marinol in Trichotillomania or Obsessive Compulsive Disorder |
- Trichotillomania
- Obsessive Compulsive Disorder
|
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score
|
14 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01093976 |
0909M72088 |
|
April 2010 |
January 2011 |
February 2011 |
March 26, 2010 |
September 27, 2013 |
September 27, 2013 |
- Ambulatory Research Center
Minneapolis, Minnesota, United States
|
|
| 23 |
NCT01024335 |
Completed
Has Results |
Dronabinol Naltrexone Treatment for Opioid Dependence |
|
- Drug: injectable naltrexone and dronabinol
- Drug: Naltrexone and placebo
|
Interventional
|
Phase 2
Phase 3 |
- New York State Psychiatric Institute
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .
- Retention
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT01024335 |
#5962 DA027124
R01DA027124
DPMC |
Domino |
January 2010 |
December 2012 |
December 2012 |
December 2, 2009 |
June 18, 2018 |
September 5, 2014 |
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 24 |
NCT03369639 |
Withdrawn |
Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Efficacy against depression as measured by the MADRS
- Efficacy against anxiety as measured by the HAM-A
- Incidence of treatment-emergent adverse effects (Safety)
- (and 3 more...)
|
0 |
All |
50 Years to 89 Years (Adult, Older Adult) |
NCT03369639 |
2017P001930 |
|
November 28, 2017 |
October 1, 2018 |
October 1, 2018 |
December 12, 2017 |
October 12, 2018 |
|
- McLean Hospital
Belmont, Massachusetts, United States
|
|
| 25 |
NCT00946348 |
Completed
Has Results |
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment |
- Schizophrenia
- Dual Diagnosis
- Schizoaffective Disorder
- (and 2 more...)
|
- Drug: Dronabinol
- Drug: Cannabis
|
Interventional
|
Phase 1 |
- Dartmouth-Hitchcock Medical Center
- National Institute on Drug Abuse (NIDA)
- Indiana University
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC).
- To Assess the Effects of Dronabinol in This Population to Determine Whether Measures of Craving, Mood and Negative Symptoms Will Improve Using the PANSS; and to Determine Whether Measures of Psychotic Symptoms and Cognitive Deficits Will Increase.
|
12 |
All |
18 Years to 50 Years (Adult) |
NCT00946348 |
R01DA013196
1R01DA026799-01
R01DA026799-01
DPMC |
|
December 2009 |
October 2012 |
October 2012 |
July 27, 2009 |
March 14, 2018 |
September 29, 2014 |
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
|
|
| 26 |
NCT00959218 |
Completed |
Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis |
- Central Neuropathic Pain in Multiple Sclerosis
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary
- Likert Numerical Rating Scale pain relief
- Pain-related sleep interference
- (and 2 more...)
|
240 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00959218 |
cnp-MS-0601 / MC-2006-01 |
|
June 2007 |
March 2010 |
April 2010 |
August 14, 2009 |
February 3, 2012 |
|
- Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie
Luedenscheid, Germany
|
|
| 27 |
NCT01020019 |
Completed
Has Results |
Combined Pharmacotherapy for Cannabis Dependency |
- Cannabis Dependence
- Marijuana Dependence
|
- Drug: Dronabinol
- Drug: Placebo
- Drug: Lofexidine
|
Interventional
|
Phase 2
Phase 3 |
- New York State Psychiatric Institute
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 21 Days of Consecutive Abstinence as Measured by the Time-line Followback.
|
156 |
All |
18 Years to 60 Years (Adult) |
NCT01020019 |
#6015
P50DA009236-16 |
D-LUCS |
January 2010 |
September 2014 |
September 2014 |
November 25, 2009 |
November 1, 2018 |
May 11, 2016 |
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 28 |
NCT02811939 |
Recruiting |
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I |
|
- Drug: Active Dronabinol
- Drug: Active Pregnenolone
- Drug: Placebo Dronabinol
- Drug: Placebo Pregnenolone
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change from Baseline: Positive and Negative Syndrome Scale (PANSS)
- Change from Baseline: Clinician Administered Dissociative Symptoms Scale (CADSS)
- Change from Baseline: Visual Analog Scale (VAS)
- (and 2 more...)
|
19 |
All |
18 Years to 55 Years (Adult) |
NCT02811939 |
1501015242.A |
THC-PREG-I |
March 2016 |
February 2018 |
February 2018 |
June 23, 2016 |
June 23, 2017 |
|
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States
|
|
| 29 |
NCT01832766 |
Terminated
Has Results |
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes |
|
- Drug: Dronabinol
- Other: Placebo Comparator
|
Interventional
|
Phase 1
Phase 2 |
- University of Colorado, Denver
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
|
- P50 Auditory Evoked Potential
- California Verbal Learning Test Change at 2 Hours From Baseline
|
13 |
All |
18 Years to 50 Years (Adult) |
NCT01832766 |
05-0359 |
|
June 2005 |
May 2010 |
May 2011 |
April 16, 2013 |
September 21, 2015 |
September 21, 2015 |
- University of Colorado Denver
Aurora, Colorado, United States
|
|
| 30 |
NCT02069366 |
Recruiting |
Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder |
- Post-Traumatic Stress Disorder
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Brain Measures
- Psychophysiology
- Expectancy Ratings
- (and 3 more...)
|
120 |
All |
21 Years to 45 Years (Adult) |
NCT02069366 |
1K01MH101123-01A1 |
|
November 2014 |
March 2019 |
December 2019 |
February 24, 2014 |
May 1, 2018 |
|
- Eugene Applebaum College of Pharmacy and Health Sciences
Detroit, Michigan, United States
|
|
| 31 |
NCT00480441 |
Completed |
Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal |
|
- Drug: Dronabinol
- Behavioral: BRENDA therapy
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cannabis dependent patients will be able to tolerate dronabinol.
- Dronabinol will attenuate cannabis withdrawal.
- The quantitative THC and self-report measurements will decrease over the time of study.
- (and 4 more...)
|
61 |
All |
18 Years to 55 Years (Adult) |
NCT00480441 |
5P60DA005186-19 |
|
August 2006 |
June 2009 |
July 2009 |
May 31, 2007 |
January 18, 2012 |
|
- Treatment Research Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 32 |
NCT00314808 |
Completed
Has Results |
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas |
- Brain Neoplasms
- Nausea
- Vomiting
|
|
Interventional
|
Phase 1 |
- Duke University
- Solvay Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability Rate
- Unacceptable Toxicity Rate
- Mean Change From Baseline in Quality of Life -- FACT-Br
- (and 2 more...)
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT00314808 |
Pro00007559
7136-05-6R0 |
|
April 2006 |
October 2011 |
April 2012 |
April 17, 2006 |
July 16, 2014 |
August 6, 2013 |
- Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Durham, North Carolina, United States
|
|
| 33 |
NCT00217971 |
Completed
Has Results |
Dronabinol Treatment for Marijuana Addiction |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- New York State Psychiatric Institute
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial
|
156 |
All |
18 Years to 60 Years (Adult) |
NCT00217971 |
#4886-NIDA-09236-11
P50DA009236
P50DA009236-11
DPMC |
MARINOL |
March 2005 |
December 2009 |
December 2009 |
September 22, 2005 |
November 28, 2018 |
November 1, 2011 |
- Research Foundation for Mental Hygiene, Inc.
New York, New York, United States
|
|
| 34 |
NCT01253408 |
Completed
Has Results |
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS) |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
|
- Colonic Transit Geometric Center at 24 Hours
- Colonic Transit Geometric Center
- Gastric Emptying Half-Time (t1/2)
- (and 3 more...)
|
36 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01253408 |
08-008314 Part A
R01DK079866
UL1RR024150 |
|
September 2009 |
December 2011 |
December 2011 |
December 3, 2010 |
May 7, 2013 |
May 7, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 35 |
NCT00418925 |
Unknown † |
Efficacy of Dronabinol for the Treatment of Cervical Dystonia |
|
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
- Dystonia Medical Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)with 3 weeks of active treatment compared to placebo
- To determine the rate and severity of adverse events within and between participants
- To observe changes within and between participants in the Global Impression Scale (GIS)
- To observe changes within and between participants in the Visual Analog Pain Scale
|
38 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00418925 |
MDC DRO 2006 |
|
September 2006 |
November 2009 |
December 2009 |
January 5, 2007 |
September 9, 2008 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
|
| 36 |
NCT00490269 |
Completed
Has Results |
Ph1 Marinol Interaction Study - Part 2 - 1 |
|
- Drug: Placebo
- Drug: Dronabinol
|
Interventional
|
Phase 1 |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects.
|
12 |
All |
18 Years to 45 Years (Adult) |
NCT00490269 |
NIDA-CPU-0013-1 |
|
October 2006 |
December 2007 |
December 2007 |
June 22, 2007 |
January 12, 2017 |
April 8, 2013 |
- Uniformed Services University of Health Science
Bethesda, Maryland, United States
|
|
| 37 |
NCT01149018 |
Unknown † |
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia |
|
- Drug: Tetrahydrocannabinol
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Hadassah Medical Organization
- Hebrew University of Jerusalem
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Meaningful change in Total score on Fibromyalgia Impact Questionnaire (FIQ)
- Meaningful change in Brief Pain Inventory average pain severity.
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT01149018 |
THC-FMS-HMO-CTIL |
|
June 2010 |
July 2012 |
October 2012 |
June 23, 2010 |
June 23, 2010 |
|
- Pain Relief Unit, Hadassah Medical Organisation
Jerusalem, Israel
|
|
| 38 |
NCT02576912 |
Recruiting |
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone |
|
- Drug: Active Delta-9-THC
- Drug: Active Pregnenolone
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
- Clinician Administered Dissociative Symptoms Scale (CADSS)
- Visual Analog Scale (VAS)
- (and 2 more...)
|
19 |
All |
18 Years to 55 Years (Adult) |
NCT02576912 |
1501015242 |
THC-Preg |
February 2015 |
December 2017 |
December 2017 |
October 15, 2015 |
June 23, 2017 |
|
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States
|
|
| 39 |
NCT00842985 |
Completed
Has Results |
Dronabinol Interactions With Cognitive Enhancing Drug in Humans |
|
|
Interventional
|
Early Phase 1 |
- Yale University
- VA Office of Research and Development
- National Institute on Drug Abuse (NIDA)
|
Other / U.S. Fed / NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing
|
53 |
All |
18 Years to 55 Years (Adult) |
NCT00842985 |
0702002357
MIRECC 00000000
P50DA009241 |
|
September 2008 |
October 2009 |
October 2009 |
February 12, 2009 |
May 30, 2017 |
December 17, 2012 |
- Department of Veterans Affairs Hospital
West Haven, Connecticut, United States
|
|
| 40 |
NCT00153192 |
Completed |
Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain |
|
- Drug: Marinol (dronabinol)
|
Interventional
|
Phase 2
Phase 3 |
- Brigham and Women's Hospital
- Solvay Pharmaceuticals
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Single-Dose Phase
- - Total pain relief (TOTPAR) at 8 hours
- Multi-Dose Phase
- (and 18 more...)
|
30 |
All |
Child, Adult, Older Adult |
NCT00153192 |
2001-P-000474
BN7894973 |
|
April 2001 |
April 2006 |
April 2006 |
September 12, 2005 |
April 26, 2013 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
|
| 41 |
NCT01755091 |
Completed
Has Results |
Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea |
|
- Drug: Dronabinol
- Drug: Placebo (for Dronabinol)
|
Interventional
|
Phase 2 |
- University of Illinois at Chicago
- Northwestern University
- University of Chicago
- Hektoen Institute for Medical Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Apnea/Hypopnea Index (AHI)
- Change in Epworth Sleepiness Scale (ESS)
- Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)
- (and 3 more...)
|
75 |
All |
21 Years to 64 Years (Adult) |
NCT01755091 |
UM1HL112856 2011-06400
UM1HL112856 |
PACE |
February 2013 |
June 2016 |
December 31, 2016 |
December 21, 2012 |
December 22, 2017 |
December 22, 2017 |
- Northwestern University
Chicago, Illinois, United States - University of Illinois at Chicago
Chicago, Illinois, United States
|
|
| 42 |
NCT03206463 |
Active, not recruiting |
Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder |
- Delta-9-Tetrahydroncannabinol
- Bipolar Disorder
- Healthy Controls
|
- Drug: 4 mg Delta-9-THC
- Drug: Placebo
- Drug: 2 mg Delta-9-THC
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Verbal memory
- Change in Executive functioning
- Attention
- (and 5 more...)
|
40 |
All |
18 Years to 55 Years (Adult) |
NCT03206463 |
2000020272 |
THC-BD |
August 1, 2017 |
July 2019 |
July 2019 |
July 2, 2017 |
June 26, 2018 |
|
- Biological Studies Unit, VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 43 |
NCT00438139 |
Terminated |
Ph1 Marinol Interaction Study - Part 1 - 1 |
|
|
Interventional
|
Phase 1 |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
6 |
All |
18 Years to 45 Years (Adult) |
NCT00438139 |
NIDA-CPU-0011-1 |
|
March 2007 |
March 2007 |
March 2007 |
February 21, 2007 |
January 16, 2017 |
|
- Uniformed Services University of Health Science
Bethesda, Maryland, United States
|
|
| 44 |
NCT00743119 |
Completed
Has Results |
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers |
|
- Drug: Placebo capsules
- Drug: Inactive marijuana (0% THC)
- Drug: Low dose Dronabinol
- (and 3 more...)
|
Interventional
|
Phase 2 |
- New York State Psychiatric Institute
- Research Foundation for Mental Hygiene, Inc.
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
|
34 |
Female |
21 Years to 45 Years (Adult) |
NCT00743119 |
5603
5P50DA009236 |
|
June 2008 |
October 2009 |
May 2013 |
August 28, 2008 |
December 11, 2017 |
December 11, 2017 |
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 45 |
NCT02492074 |
Not yet recruiting |
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study |
- Healthy Volunteers
- Modeling Psychosis
|
- Drug: Delta-9-tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Positive and Negative Syndrome Scale (total score, PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and D2-receptor availability
- Change in PANSS subscores and clusters (baseline to post drug intake)
- Change in Digit Symbol Coding
- (and 11 more...)
|
60 |
Male |
18 Years to 45 Years (Adult) |
NCT02492074 |
GEI-TCP I |
|
April 2019 |
April 2020 |
May 2020 |
July 8, 2015 |
March 15, 2018 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany
|
|
| 46 |
NCT01964404 |
Recruiting |
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? |
- Schizophrenia
- Dual Diagnosis
- Psychotic Disorder
- Cannabis Use Disorder
|
- Drug: Marijuana
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Alan Green
- Columbia University
- Harvard Medical School
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain Reward Circuit Activation
- Resting State Connectivity
|
240 |
All |
18 Years to 55 Years (Adult) |
NCT01964404 |
1R01DA034699-01A1 |
|
July 2014 |
March 2020 |
April 2020 |
October 17, 2013 |
March 23, 2018 |
|
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States - University of Vermont
Burlington, Vermont, United States
|
|
| 47 |
NCT00893074 |
Completed
Has Results |
The Effect of Prescription Medications in Marijuana Users |
|
- Drug: Dronabinol 30mg/day
- Drug: Dronabinol 60mg/day
- Drug: Dronabinol 120mg/day
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Johns Hopkins University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Peak Effect of Marijuana Withdrawal
- Subjective "Drug Effect" After Smoked Marijuana
- Heart Rate
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00893074 |
NA_00026278
R01DA025044 |
|
April 2009 |
October 2011 |
October 2011 |
May 5, 2009 |
August 3, 2017 |
August 3, 2017 |
- Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
|
|
| 48 |
NCT00642499 |
Completed |
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting |
- Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
- HIV Infections
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The absence of nausea as indicated by a visual analog scale (VAS) score < 5 mm
- Number of episodes vomiting/retching
- Duration of nausea, vomiting/retching
- (and 2 more...)
|
103 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00642499 |
S175.2.101 |
|
August 2003 |
April 2005 |
April 2005 |
March 25, 2008 |
April 2, 2008 |
|
- Site 911
Bakersfield, California, United States - Site 919
Fresno, California, United States - Site 924
Los Angeles, California, United States - (and 33 more...)
|
|
| 49 |
NCT02335060 |
Active, not recruiting |
N-acetylcysteine Effects on Tetrahydrocannabinol |
|
- Drug: Delta-9-THC
- Drug: N-acetylcysteine
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Positive and Negative Symptom Scale for Schizophrenia (PANSS)
- Clinician Administered Dissociative Symptoms Scale (CADSS)
- Visual Analog Scale (VAS)
- (and 3 more...)
|
36 |
All |
18 Years to 55 Years (Adult) |
NCT02335060 |
1402013406 |
|
March 2014 |
January 2019 |
January 2019 |
January 9, 2015 |
June 6, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 50 |
NCT00553059 |
Completed |
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer |
- Chemotherapy-induced Nausea and Vomiting
- Unspecified Adult Solid Tumor, Protocol Specific
|
- Drug: dexamethasone
- Drug: dronabinol
- Drug: palonosetron hydrochloride
- Other: placebo
|
Interventional
|
Phase 3 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Solvay Pharmaceuticals
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Number of Participants with Total protection
- Acute, Delayed and Overall Total Protection
- Complete response and Complete Protection for the acute, delayed, and overall periods
|
62 |
All |
18 Years and older (Adult, Older Adult) |
NCT00553059 |
2006-0841
MDA-2006-0841
CDR0000573510
NCI-2009-00637 |
|
May 2008 |
August 2014 |
|
November 5, 2007 |
September 5, 2014 |
|
- Cancer Research for the Ozarks
Springfield, Missouri, United States - CCOP - Greenville
Greenville, South Carolina, United States - University of Texas M.D. Anderson CCOP Research Base
Houston, Texas, United States - Vermont Cancer Center at University of Vermont
Burlington, Vermont, United States
|
|
| 51 |
NCT00760695 |
Completed |
Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa |
|
- Drug: dronabinol
- Drug: placebo
|
Interventional
|
Phase 3 |
- Odense University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Weight gain
- Eating Disorder Inventory (EDI) scale
- Motor and inner restlessness (estimated by accelerometry)
- Endocrine parameters
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00760695 |
033 |
|
October 2008 |
December 2011 |
December 2011 |
September 26, 2008 |
May 10, 2013 |
|
- Odense University Hospital
Odense, Denmark
|
|
| 52 |
NCT01893424 |
Completed |
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) |
|
- Drug: Sativex buccal spray
- Drug: CBD-THC-Piperine-PNL capsule
|
Interventional
|
Phase 1 |
- Hadassah Medical Organization
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Pharmacokinetic parameters of THC and CBD
- exposure to the metabolites of the study drugs
|
12 |
Male |
18 Years to 45 Years (Adult) |
NCT01893424 |
0658-12-HMO-CTIL |
|
August 2013 |
January 2014 |
January 2015 |
July 9, 2013 |
March 24, 2016 |
|
- Hadassah medical organization
Jerusalem, Israel
|
|
| 53 |
NCT00123201 |
Completed |
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache |
- Migraine With Aura
- Migraine Without Aura
|
|
Interventional
|
Phase 2 |
- Solvay Pharmaceuticals
- Nektar Therapeutics
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00123201 |
S175.2.103 |
|
September 2005 |
March 2007 |
March 2007 |
July 22, 2005 |
January 16, 2015 |
|
- Site 10
Huntsville, Alabama, United States - Site 8
Huntsville, Alabama, United States - Site 11
Tucson, Arizona, United States - (and 26 more...)
|
|
| 54 |
NCT00316563 |
Completed |
Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study |
- Cancer
- Anorexia
- Taste Disorders
- Olfactory Disorders
|
- Drug: Marinol (Dronabinol)
- Other: Placebo
|
Interventional
|
Phase 2 |
- Alberta Health Services
- University of Alberta
- AHS Cancer Control Alberta
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Total caloric intake
- self-perceived chemosensory ability
- palatable food intake
- (and 3 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT00316563 |
PS-8-0008 |
|
August 2006 |
|
November 2009 |
April 21, 2006 |
February 9, 2010 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada - Royal Victoria Hospital
Montreal, Quebec, Canada
|
|
| 55 |
NCT02291536 |
Completed |
Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) |
|
- Drug: tetrahydrocannabinol
- Drug: cannabidiol
- Other: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Correctly identified emotional pictures during the attentional blink period
- Reaction time to correctly identified emotional pictures during the attentional blink period
|
20 |
Male |
18 Years to 65 Years (Adult, Older Adult) |
NCT02291536 |
AB_THC_CBD |
AB_THC_CBD |
February 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 56 |
NCT00757822 |
Completed
Has Results |
Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients |
- Postoperative Nausea and Vomiting
|
- Drug: Dronabinol
- Drug: Ondansetron
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Incidence of Postoperative Nausea and Vomiting
- Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale
- Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery
- (and 5 more...)
|
216 |
All |
18 Years and older (Adult, Older Adult) |
NCT00757822 |
CLIN-008-08S
0167_2008I |
PONV |
December 2009 |
December 2013 |
April 2015 |
September 23, 2008 |
May 13, 2016 |
May 13, 2016 |
- Central Arkansas Veterans Healthcare System-John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas, United States
|
|
| 57 |
NCT00812851 |
Completed |
Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) |
- Cramps
- Amyotrophic Lateral Sclerosis
|
|
Interventional
|
Not Applicable |
- Cantonal Hospital of St. Gallen
- ALS Association
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00812851 |
THC SG |
|
April 2005 |
April 2008 |
April 2008 |
December 22, 2008 |
February 19, 2009 |
|
- Kantonsspital St.Gallen
St.Gallen, Switzerland
|
|
| 58 |
NCT03646552 |
Recruiting |
A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea |
|
|
Interventional
|
Phase 2 |
- Therapix Biosciences Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A Significant Change in AHI Index
- A Change in Oxygen Desaturation Index (ODI)
|
30 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03646552 |
0079-17-ASMC |
|
June 4, 2018 |
April 2019 |
April 2019 |
August 24, 2018 |
August 24, 2018 |
|
- Assuta HaShalom
Tel Aviv, Israel
|
|
| 59 |
NCT00642512 |
Completed |
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting |
- Chemotherapy Induced Nausea and Vomiting
|
- Drug: dronabinol
- Drug: ondansetron
- Drug: dronabinol/ondansetron
- Drug: placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Total response of nausea and vomiting/retching was defined as no vomiting and/or retching, an intensity of nausea of < 5 mm on the visual analog scale (VAS) and no use of rescue medication.
- Complete responder rate (no vomiting/retching, intensity of nausea of ≤ 30 mm on the VAS and no use of rescue medication)
- Presence or absence of nausea
- (and 2 more...)
|
64 |
All |
18 Years and older (Adult, Older Adult) |
NCT00642512 |
S175.3.102 |
|
July 2003 |
July 2004 |
July 2004 |
March 25, 2008 |
April 3, 2008 |
|
- Site 970
Tucson, Arizona, United States - Site 950
Anaheim, California, United States - Site 925
Fountain Valley, California, United States - (and 40 more...)
|
|
| 60 |
NCT02487381 |
Completed |
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids |
- Healthy
- Modeling Psychosis
|
- Drug: delta-9-tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Positive and Negative Syndrome Scale total score (PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and neural synchrony.
- Change in Positive and Negative Syndrome Scale (PANSS) subscores and clusters (baseline to post drug intake)
- Change in neuropsychological parameters
- (and 5 more...)
|
60 |
Male |
18 Years to 45 Years (Adult) |
NCT02487381 |
GEI-TCP II |
|
April 2015 |
July 2015 |
August 2015 |
July 1, 2015 |
August 17, 2015 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany
|
|
| 61 |
NCT02781519 |
Recruiting |
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans |
|
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Rewarding Effects measured by Visual Analog Scale (VAS)
- Verbal Learning: measured by Rey Auditory Verbal Learning Test (AVLT)
|
100 |
All |
18 Years to 55 Years (Adult) |
NCT02781519 |
1505015940 |
THC-Gender |
June 2015 |
June 2020 |
June 2020 |
May 24, 2016 |
June 26, 2018 |
|
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States
|
|
| 62 |
NCT03651726 |
Not yet recruiting |
A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome |
|
- Drug: THX-110 (dronabinol plus PEA)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Therapix Biosciences Ltd.
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in YGTSS-TTS
- Response to treatment according to YGTSS-TTS
- YGTSS-TTS as a binary responder criterion and as a continuous endpoint at week 7 of the double-blind phase
- (and 14 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03651726 |
THX-G18-001 |
|
August 2018 |
November 2019 |
November 2019 |
August 29, 2018 |
August 29, 2018 |
|
- Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie
Hannover, Germany - LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie
Munich, Germany
|
|
| 63 |
NCT00000737 |
Completed |
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome |
- Cachexia
- HIV Infections
- HIV Wasting Syndrome
|
- Drug: Dronabinol
- Drug: Megestrol acetate
|
Interventional
|
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Roxane Laboratories
- Bristol-Myers Squibb
|
NIH / Industry |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
56 |
All |
18 Years and older (Adult, Older Adult) |
NCT00000737 |
DATRI 004 |
|
|
|
|
August 31, 2001 |
August 25, 2008 |
|
- Denver Public Health Dept
Denver, Colorado, United States - Univ of Illinois
Chicago, Illinois, United States - Univ of Kansas School of Medicine
Wichita, Kansas, United States - (and 6 more...)
|
|
| 64 |
NCT00377468 |
Unknown † |
Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) |
- Complex Regional Pain Syndromes
- CRPS
|
- Drug: Delta9-Tetrahydrocannabinol
|
Interventional
|
Phase 2 |
- Ludwig-Maximilians - University of Munich
- German Federal Ministry of Education and Research
- German Research Network on Neuropathic Pain
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Incidence of chronic pain at one year assessed with Visual Analogue Scale (VAS)
- Changes in somatosensory phenotype at one year assessed with Quantitative Sensory Testing (QST)
- Motor function of the affected extremity at one year assessed with a biometric evaluation
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT00377468 |
2310106
Eudra-CT: 2006-000439-85 |
|
September 2006 |
|
December 2008 |
September 18, 2006 |
June 30, 2008 |
|
- Department of Anesthesiology, Interdisciplinary Pain Clinic Grosshadern, Universitiy of Munich
Munich, Germany
|
|
| 65 |
NCT01786109 |
Completed
Has Results |
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome |
|
- Drug: Dronabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Michael Camilleri
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Center for Research Resources (NCRR)
- Mayo Clinic
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
|
- Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)
- Postprandial Change in Colonic Tone
- Post-treatment Sensory Threshold for First Perception of Pain
- (and 5 more...)
|
75 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01786109 |
08-008314 Part B
R01DK079866
UL1RR024150 |
|
September 2009 |
December 2011 |
December 2011 |
February 7, 2013 |
March 14, 2013 |
March 13, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 66 |
NCT00176163 |
Completed |
Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain |
|
- Behavioral: Operant behavioral treatment; Drug: THC
|
Interventional
|
Phase 2 |
- Heidelberg University
- Central Institute of Mental Health, Mannheim
- University of Mannheim
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Impairment by pain
- Pain intensity
- physical function and emotional state assessed by questionnaires
- (and 4 more...)
|
240 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00176163 |
kfg107 |
|
August 2005 |
|
May 2009 |
September 15, 2005 |
February 2, 2010 |
|
|
|
| 67 |
NCT01551511 |
Completed |
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain |
- Pancreatitis, Chronic
- Abdominal Pain
- Chronic Pain
|
- Drug: Tetrahydrocannabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Radboud University
- European Union
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Average VAS pain
- EEG
- QST
- (and 5 more...)
|
29 |
All |
18 Years and older (Adult, Older Adult) |
NCT01551511 |
HEEL-2011-02 |
|
October 2012 |
June 2014 |
June 2014 |
March 12, 2012 |
October 28, 2014 |
|
- Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
|
|
| 68 |
NCT01323569 |
Completed |
Abuse Potential of Sativex |
- Evaluation of Abuse Potential of Sativex
|
- Drug: Sativex
- Drug: Placebo
- Drug: Marinol
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Comparison of Subjective Drug Value (SDV)(Balance of effects) between Marinol and Sativex
- Comparison of Bipolar Drug Liking VAS (Balance of effects) between Marinol and Sativex
- Comparison of Addiction Research Centre Inventory (ARCI) MBG (Positive effects) between Marinol and Sativex
- (and 7 more...)
|
58 |
All |
19 Years to 45 Years (Adult) |
NCT01323569 |
GWCP0605 |
|
February 2008 |
June 2008 |
June 2008 |
March 25, 2011 |
June 14, 2013 |
|
- DecisionLine Clinical Research Corporation
Toronto, Ontario, Canada
|
|
| 69 |
NCT02061020 |
Completed |
Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users |
- Occasional (1-2 Joints Per Week) and Chronic (1-2 Joints Per Day) Cannabis Users
|
- Drug: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
|
Interventional
|
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Ability to drive a motor vehicle measured using a driving simulator
- Psychomotor Vigilance Test (PVT) measures
- THC pharmacokinetics of occasional and chronic users over 24 hours
- 24 hoursTHC pharmacokinetics (AUC, T1 / 2, CMAX) and its relationships with genotype CYP2C9 * 3
|
37 |
Male |
18 Years to 25 Years (Adult) |
NCT02061020 |
AOR12144 / P111114
2013-A00245-40 |
VIGICANN |
January 2014 |
July 2015 |
March 2016 |
February 12, 2014 |
June 9, 2016 |
|
- Raymond Poincare Hospital
Garches, France
|
|
| 70 |
NCT00079560 |
Completed |
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS |
|
|
Interventional
|
Phase 1
Phase 2 |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
|
30 |
All |
21 Years to 50 Years (Adult) |
NCT00079560 |
1R01DA012698-01A1 |
|
December 2001 |
August 2004 |
August 2005 |
March 10, 2004 |
January 11, 2017 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 71 |
NCT00362089 |
Completed |
Fatty Acids During Pregnancy and Lactation and Body Fat Mass in Newborns |
|
- Dietary Supplement: Marinol D-40
|
Interventional
|
Not Applicable |
- Technische Universität München
- Else Kröner-Fresenius-Foundation; International Unilever-Foundation; Danone Research
- EU funding by EARNEST consortium;German Ministry of Education and Research GF-GFGI01120708)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- amount of fat mass in the offspring
- offspring body height
- head circumference of newborns, infants and children
- (and 19 more...)
|
208 |
Female |
18 Years to 43 Years (Adult) |
NCT00362089 |
EKFZ001_CN
INFAT |
|
June 2006 |
November 2010 |
November 2010 |
August 9, 2006 |
February 4, 2014 |
|
- Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Technische Universität München
Munich, Germany
|
|
| 72 |
NCT01740960 |
Completed |
Safety and Tolerability of Namisol in the Elderly |
|
- Drug: delta-9-tetrahydrocannabinol
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- THC adverse effects checklist and self-reporting by the subjects
- Body Sway Test (SwayStar™)
- Visual analogue scales, subtest "feeling high"
- (and 2 more...)
|
12 |
All |
65 Years and older (Older Adult) |
NCT01740960 |
GER001-02-03
2012-001841-42 |
THC |
August 2012 |
December 2012 |
December 2012 |
December 4, 2012 |
January 7, 2014 |
|
- Radboud University Medical Centre, department of Geriatrics
Nijmegen, Gelderland, Netherlands
|
|
| 73 |
NCT02291562 |
Completed |
Effects of THC and CBD on Human Episodic Memory Function |
|
- Drug: Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Changes in BOLD (blood oxygen level dependent) responses
- Changes in behavioral measures
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT02291562 |
LOGIN_EpMem |
|
July 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 74 |
NCT00628706 |
Completed |
Investigating the Acute Effects of THC on Functional Brain Systems |
- Reward
- Tetrahydrocannabinol
- Endocannabinoids
- (and 2 more...)
|
- Drug: Delta9-tetrahydrocannabinol (THC)
|
Interventional
|
Phase 1 |
- UMC Utrecht
- Center for Human Drug Research
- Leiden University Medical Center
- TI Pharma
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- The main study parameter is the blood oxygen level dependent (BOLD) signal.
- Behavioral parameters (two VAS questionnaires)
- Cerebral blood flow (ASL)
- (and 2 more...)
|
12 |
Male |
18 Years to 45 Years (Adult) |
NCT00628706 |
THC-phMRI-01 |
FIX |
April 2008 |
September 2008 |
September 2008 |
March 5, 2008 |
February 18, 2009 |
|
- University Medical Center Utrecht
Utrecht, Netherlands
|
|
| 75 |
NCT03655717 |
Recruiting |
Using Imaging to Assess Effects of THC on Brain Activity |
- Intoxication Alcohol
- Intoxication THC
- Intoxication Combined Alcohol THC
|
- Drug: Dronabinol
- Drug: Ethanol
- Drug: Placebo Dronabinol
- Drug: Placebo Ethanol
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Change on fNIRS (HbO) measure of prefrontal brain activity and connectivity at rest as an effect of THC intoxication
- Change on fNIRS (HbO) measure of prefrontal brain activity during memory task as an effect of THC intoxication
- Change on fNIRS (HbO) measure of prefrontal brain activity and connectivity at rest as an effect of THC + ethanol intoxication
- Change on fNIRS (HbO) measure of prefrontal brain activity during memory task ) as an effect of THC + ethanol intoxication
|
50 |
All |
21 Years to 55 Years (Adult) |
NCT03655717 |
2015P001516
R42DA043977 |
fNIRS |
November 5, 2018 |
September 17, 2020 |
December 17, 2020 |
August 31, 2018 |
December 6, 2018 |
|
- Center for Addiction Medicine, Massachusetts General Hospital, Dept. of Psychiatry
Boston, Massachusetts, United States
|
|
| 76 |
NCT00218504 |
Completed |
Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2 |
|
- Drug: Tetrahydrocannabinol
|
Observational
|
|
- Wayne State University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
20 |
All |
21 Years to 45 Years (Adult) |
NCT00218504 |
NIDA-19236-2
R21DA019236
DPMCDA |
|
December 2005 |
|
October 2009 |
September 22, 2005 |
June 5, 2012 |
|
- Wayne State University
Detroit, Michigan, United States
|
|
| 77 |
NCT01598207 |
Completed
Has Results |
The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain |
|
- Drug: Marinol
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Yehudith Assouline-Dayan
- University of Iowa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Frequency of Chest Pain Episodes
- Frequency of Chest Pain in Treatment Group vs Baseline
- Intensity of Chest Pain Episodes
- (and 4 more...)
|
13 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01598207 |
201003768 |
|
February 2011 |
May 2014 |
May 2014 |
May 15, 2012 |
April 28, 2017 |
April 28, 2017 |
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
|
| 78 |
NCT01562483 |
Completed |
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain |
- Postsurgical Pain
- Abdominal Pain
- Chronic Pain
|
- Drug: Tetrahydrocannabinol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Radboud University
- European Union
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Average VAS pain
- Electroencephalogram (EEG)
- Quantitative Sensory Testing (QST)
- (and 4 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT01562483 |
HEEL-2011-03 |
|
October 2012 |
June 2014 |
June 2014 |
March 23, 2012 |
October 28, 2014 |
|
- Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
|
|
| 79 |
NCT01318369 |
Completed |
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain |
- Cannabinoid
- Tetrahydrocannabinol
- Chronic Pancreatitis
- Abdominal Pain
|
- Drug: Namisol
- Drug: Diazepam
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain intensity (VAS pain)
- EEG
- QST
- Body sway
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01318369 |
HEEL-2011-01 |
Delta-pain |
October 2011 |
May 2013 |
May 2013 |
March 18, 2011 |
July 9, 2013 |
|
- Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands
|
|
| 80 |
NCT01608217 |
Completed |
Delta-THC in Dementia |
- Behavioural Disturbances
- Pain
- Dementia
- (and 2 more...)
|
- Drug: delta-9-tetrahydrocannabinol (delta-THC)
- Drug: Placebo
- Drug: Acetaminophen
|
Interventional
|
Phase 2 |
- Radboud University
- Health Valley, Netherlands
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Neuropsychiatric Inventory (NPI)
- Pain Assessment Checklist for Seniors with Limited Ability to Communicate Dutch version (PACSLAC-D)
- Caregiver Clinical Global Impression of Change (CCGIC)
- (and 6 more...)
|
50 |
All |
40 Years and older (Adult, Older Adult) |
NCT01608217 |
GER001-02-02
2011-005289-39
NL38617.091.12 |
|
June 2012 |
June 2014 |
June 2014 |
May 31, 2012 |
June 30, 2014 |
|
- Radboud university medical center, department of Geriatrics
Nijmegen, Gelderland, Netherlands - Vincent van Gogh Institute for Psychiatry, department of Elderly
Venlo, Limburg, Netherlands
|
|
| 81 |
NCT00982982 |
Active, not recruiting |
Effects of Delta-9-THC and Iomazenil in Healthy Humans |
- Schizophrenia
- Mental Disorders
- Psychotic Disorders
|
- Drug: THC and Iomazenil
- Drug: Placebo (control)
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Clinician Administered Dissociative Symptoms Scale
- Positive and Negative Symptom Scale
- Visual Analog Scale
- (and 2 more...)
|
60 |
Male |
18 Years to 55 Years (Adult) |
NCT00982982 |
0901004662 |
|
February 2009 |
June 2018 |
June 2018 |
September 23, 2009 |
December 2, 2017 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 82 |
NCT02310347 |
Unknown † |
Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake |
|
- Drug: dronabinol
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Behavioural responses to food images and food intake
- Gut peptide responses
|
18 |
All |
18 Years to 60 Years (Adult) |
NCT02310347 |
S54673
2012-003017-33 |
|
December 2014 |
September 2016 |
April 2017 |
December 8, 2014 |
October 26, 2016 |
|
- University Hospitals Leuven, campus Gasthuisberg
Leuven, Belgium
|
|
| 83 |
NCT03471585 |
Completed |
Effects of THC on Emotional Memory Retrieval |
|
- Drug: THC
- Drug: Placebo oral capsule
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Emotional Memory
- DRM Memory
- Addiction Research Centre Inventory Marijuana Scale
- (and 4 more...)
|
23 |
All |
18 Years to 35 Years (Adult) |
NCT03471585 |
IRB16-1132 |
TARE |
February 15, 2017 |
October 4, 2017 |
October 4, 2017 |
March 20, 2018 |
March 20, 2018 |
|
- University of Chicago
Chicago, Illinois, United States
|
|
| 84 |
NCT03398083 |
Completed |
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam |
|
- Drug: THC
- Drug: Alprazolam
- Drug: Placebo oral capsule
- Drug: CBD
|
Interventional
|
Phase 1 |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Diagnostic
|
- Visual Analog Scale
- Incidence of Increased Vital Signs
- Incidence of Increased ECG Reading
- Incidence of Clinically Significant Laboratory Values
|
42 |
All |
18 Years to 55 Years (Adult) |
NCT03398083 |
NIDA-CBD-Phase1-001 |
|
December 4, 2017 |
May 30, 2018 |
May 30, 2018 |
January 12, 2018 |
June 14, 2018 |
|
- Debra Kelsh, MD
Overland Park, Kansas, United States
|
|
| 85 |
NCT03756974 |
Not yet recruiting
New |
BX-1 in Spasticity Due to MS |
- Spasticity Due to Multiple Sclerosis
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Responder analysis: proportion of patients showing improvement in spasticity of 18% or more in average NRS-S assessment at end of treatment
- Responder analysis: proportion of patients showing improvement in spasticity (change from baseline) of 30% or more in average NRS-S assessment at end of treatment (Visit 6)
- Responder analysis: proportion of patients showing improvement in spasticity (change from baseline) of 50% or more in average NRS-S assessment at end of treatment (Visit 6)
- (and 18 more...)
|
384 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03756974 |
DroSpas-1 |
|
November 2018 |
February 2020 |
February 2020 |
November 28, 2018 |
November 28, 2018 |
|
- Investigative Site
Choceň, Czechia - Investigative Site
Havířov, Czechia - Investigative Site
Hradec Králové, Czechia - (and 45 more...)
|
|
| 86 |
NCT01591629 |
Active, not recruiting |
The Effects of ∆-9-THC and Naloxone in Humans |
|
- Drug: Naloxone
- Drug: Delta-9-THC
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Behavioral Measures
- Visual analog scales
- Clinician Administered Dissociative States Scales (CADSS)
- (and 5 more...)
|
56 |
All |
18 Years to 55 Years (Adult) |
NCT01591629 |
1108008940 |
|
July 2011 |
July 2018 |
July 2018 |
May 4, 2012 |
November 30, 2017 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 87 |
NCT00373503 |
Completed |
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse |
|
- Drug: Lofexidine
- Drug: dronabinol
- Drug: Marijuana
|
Interventional
|
Phase 2 |
- New York State Psychiatric Institute
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- marijuana relapse
- marijuana withdrawal symptoms
|
8 |
All |
21 Years to 45 Years (Adult) |
NCT00373503 |
4942
R01DA019239 |
|
August 2005 |
June 2007 |
September 2008 |
September 8, 2006 |
February 5, 2013 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 88 |
NCT02485158 |
Completed
Has Results |
Individual Differences in the Response to Drugs |
|
- Drug: THC
- Drug: AMP
- Drug: ALC
- (and 2 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration
- Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration
- Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration
- (and 11 more...)
|
28 |
All |
21 Years to 35 Years (Adult) |
NCT02485158 |
IRB13-0534 |
TDS |
July 2013 |
December 2013 |
December 2013 |
June 30, 2015 |
November 29, 2016 |
November 29, 2016 |
|
|
| 89 |
NCT02102113 |
Recruiting |
Probing the Cannabinoid System in Individuals With a Family History of Psychosis |
- Psychosis
- Cannabis Use
- THC
- (and 2 more...)
|
- Drug: Placebo
- Drug: Very Low Dose THC
- Drug: Low Dose THC
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Other
|
- Positive and Negative Symptom Scale for Schizophrenia (PANSS)
- Clinician Administered Dissociative Symptoms Scale (CADSS)
- Visual Analog Scale (VAS)
- (and 2 more...)
|
72 |
All |
18 Years to 55 Years (Adult) |
NCT02102113 |
1310012948 |
|
January 2014 |
April 2019 |
April 2019 |
April 2, 2014 |
June 6, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 90 |
NCT00678730 |
Active, not recruiting |
Pharmacogenetics of Cannabinoid Response |
|
- Drug: delta 9 tetrahydrocannabinol
|
Interventional
|
Phase 1 |
- Yale University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
|
162 |
All |
18 Years to 55 Years (Adult) |
NCT00678730 |
0706002754 |
|
July 2007 |
July 2018 |
July 2018 |
May 15, 2008 |
June 23, 2017 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 91 |
NCT00682929 |
Terminated
Has Results |
Cannabis for Spasticity in Multiple Sclerosis |
|
- Drug: Inhaled Cannabis
- Drug: Oral THC
- Drug: Oral Placebo
- Drug: Inhaled placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of California, Davis
- National Multiple Sclerosis Society
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Week 0 to Week 3 in the Rate of Torque Increase, Flexion
- Change From Week 0 to Week 3 in the Rate of Torque Increase, Extension
- Change From Week 0 to Week 7 in the Rate of Torque Increase, Flexion
- (and 51 more...)
|
41 |
All |
21 Years and older (Adult, Older Adult) |
NCT00682929 |
251429
MS Society Award # RG 3781-A-1 |
|
April 14, 2004 |
August 17, 2011 |
August 17, 2011 |
May 23, 2008 |
May 18, 2018 |
May 18, 2018 |
- University of California Davis Medical Center
Sacramento, California, United States
|
|
| 92 |
NCT01302340 |
Completed |
Delta-THC in Behavioral Disturbances in Dementia |
|
- Drug: Delta-THC
- Drug: placebo
|
Interventional
|
Phase 2 |
- Radboud University
- European Union
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Neuropsychiatric Inventory (NPI)
- Cohen-Mansfield Agitation Inventory (CMAI)
- Zarit Burden Scale (ZBS)
- (and 6 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT01302340 |
GER001-02-01
2009-019329
2010-024577-39
Supplies Investigational Drug |
|
September 2011 |
December 2013 |
December 2013 |
February 24, 2011 |
January 22, 2014 |
|
- Radboud university medical center
Nijmegen, Gelderland, Netherlands - Vincent van Gogh Institute for Psychiatry, department of Elderly
Venray, Limburg, Netherlands
|
|
| 93 |
NCT02112292 |
Completed |
The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking |
|
- Drug: tetrahydrocannabinol
- Drug: cannabidiol
- Drug: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Relation between sweet taste intensity and liking
- Ranking order of pleasantness of different drinks with different levels of sucrose.
- Preferences for different kinds of foods
- (and 3 more...)
|
10 |
Male |
18 Years to 35 Years (Adult) |
NCT02112292 |
NL44758.081.13
2013-002555-14 |
Sweed |
April 2014 |
April 16, 2015 |
April 16, 2015 |
April 11, 2014 |
May 23, 2017 |
|
- Wageningen University
Wageningen, Gelderland, Netherlands
|
|
| 94 |
NCT02956226 |
Active, not recruiting |
Cannabinoids for Behavioral Problems in Children With ASD |
|
- Drug: Cannabinoids - 99% pure cannabinoids mix
- Drug: Placebo
- Drug: Cannabinoids - whole plant extract
|
Interventional
|
Phase 2 |
- Shaare Zedek Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition.
- Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition.
- Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject differences between the placebo condition and the pure cannabinoids condition and between the whole plant extract condition and the pure cannabinoids condition.
- (and 3 more...)
|
150 |
All |
5 Years to 21 Years (Child, Adult) |
NCT02956226 |
CBA |
CBA |
January 2017 |
January 2019 |
July 2019 |
November 7, 2016 |
August 7, 2018 |
|
- Shaare Zedek Medical Center
Jerusalem, Israel
|
|
| 95 |
NCT01748799 |
Completed
Has Results |
Fixed or Self-Titrated Dosages of Sativex on Cannabis Users |
|
- Drug: Sativex
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Feasibility
- Tolerability of Sativex in Persons That Are Cannabis Dependent
- Cannabis Withdrawal
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT01748799 |
103/2011
243152 |
|
February 2013 |
September 2014 |
September 2014 |
December 13, 2012 |
February 1, 2016 |
February 1, 2016 |
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 96 |
NCT03744091 |
Recruiting
New |
Evaluation of the Pharmacokinetics of Prana P1 Capsules |
|
|
Interventional
|
Phase 1 |
- The University of The West Indies
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Peak Plasma Concentration( Cmax) of following a single dose of 10 mg Prana 1
- Peak Plasma Concentration( Cmax) of following a single dose of 20 mg Prana 1
- Number of participants with treatment related adverse events as assessed by CTCAE v 5.0
- Number of participants who discontinue treatment due to side effects
|
12 |
Male |
18 Years to 55 Years (Adult) |
NCT03744091 |
PR0PK1 |
|
July 16, 2018 |
December 23, 2018 |
January 23, 2019 |
November 16, 2018 |
November 16, 2018 |
|
- Tropical Metabolism Research Unit, Caribbean Institute for Health Reserach, University of the West Indies, Mona
Kingston, Jamaica
|
|
| 97 |
NCT03106363 |
Recruiting |
Combined Alcohol and Cannabis Effects on Skills of Young Drivers |
|
- Drug: delta 9 tetrahydrocannabinol
- Drug: placebo delta 9 tetrahydrocannabinol
- Drug: Alcohol
- Drug: Placebo alcohol
|
Interventional
|
Early Phase 1 |
- Centre for Addiction and Mental Health
- Canadian Institutes of Health Research (CIHR)
- Health Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Psychomotor impairment: Standard deviation of lateral position
- Psychomotor impairment: Mean speed, standard deviation of speed, and maximum speed
- Psychomotor impairment: Minimum time to collision and brake latency
- (and 7 more...)
|
70 |
All |
19 Years to 25 Years (Adult) |
NCT03106363 |
123-2015 |
|
July 4, 2017 |
December 2019 |
January 2020 |
April 10, 2017 |
September 27, 2018 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 98 |
NCT01887301 |
Completed |
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic analysis - Unbound maximum plasma concentration (Cmax(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- Pharmacokinetic analysis - Unbound area under the concentration-time curve calculated to the last observable concentration at time t (AUC0-t(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- Pharmacokinetic analysis - Unbound Area under the concentration-time curve from time zero to infinity (AUC0-inf(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- (and 7 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT01887301 |
GWCP10114 |
|
July 2013 |
May 2014 |
May 2014 |
June 26, 2013 |
June 4, 2014 |
|
- Anaheim Clinical Trials, LLC
Anaheim, California, United States - Clinical Pharmacology of Miami, Inc.
Miami, Florida, United States
|
|
| 99 |
NCT00943930 |
Completed |
Marijuana Drug Discrimination and Self-Administration |
|
- Drug: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
|
Observational
|
|
- Wayne State University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To test the ability of oral THC to alter the discriminative stimulus and reinforcing effects of smoked marijuana.
- Subjective effects: Self-report questionnaires regarding subjective drug effects, craving, withdrawal symptoms, and marijuana choice will be assessed. Physiological effects: Heart rate, skin temperature, and blood pressure will be monitored.
|
29 |
All |
21 Years to 45 Years (Adult) |
NCT00943930 |
NIDA DA026761
R01DA026761-01 |
DDC |
April 2009 |
December 2012 |
December 2014 |
July 22, 2009 |
April 28, 2016 |
|
- Wayne State University
Detroit, Michigan, United States
|
|
| 100 |
NCT03172741 |
Withdrawn |
The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis |
|
- Drug: Medical Marijuana
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Colorado State University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Leg Strength
- Fatigue Severity Scale
- 25 foot walk test
- (and 7 more...)
|
0 |
All |
21 Years to 74 Years (Adult, Older Adult) |
NCT03172741 |
16-6964H |
|
January 2017 |
January 2018 |
January 2018 |
June 1, 2017 |
July 18, 2018 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: